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Radioembolization (RE) of liver cancer with 90Y-microspheres has been applied in the last
two decades with notable responses and acceptable toxicity. Two types of microspheres
are available, glass and resin, the main difference being the activity/sphere. Generally,
administered activities are established by empirical methods and differ for the two types.
Treatment planning based on dosimetry is a prerogative of few centers, but has notably
gained interest, with evidence of predictive power of dosimetry on toxicity, lesion response,
and overall survival (OS). Radiobiological correlations between absorbed doses and toxi-
city to organs at risk, and tumor response, have been obtained in many clinical studies.
Dosimetry methods have evolved from the macroscopic approach at the organ level to
voxel analysis, providing absorbed dose spatial distributions and dose–volume histograms
(DVH). The well-known effects of the external beam radiation therapy (EBRT), such as the
volume effect, underlying disease influence, cumulative damage in parallel organs, and
different tolerability of re-treatment, have been observed also in RE, identifying in EBRT
a foremost reference to compare with. The radiobiological models – normal tissue com-
plication probability and tumor control probability – and/or the style (DVH concepts) used
in EBRT are introduced in RE. Moreover, attention has been paid to the intrinsic different
activity distribution of resin and glass spheres at the microscopic scale, with dosimet-
ric and radiobiological consequences. Dedicated studies and mathematical models have
developed this issue and explain some clinical evidences, e.g., the shift of dose to higher
toxicity thresholds using glass as compared to resin spheres. This paper offers a compre-
hensive review of the literature incident to dosimetry and radiobiological issues in RE, with
the aim to summarize the results and to identify the most useful methods and information
that should accompany future studies.
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INTRODUCTION
In the past two decades, radioembolization (RE) with 90Y-
microspheres has emerged as a safe and efficacious treatment
modality for unresectable primary and secondary liver malignan-
cies. The rationale is based on the fact that both the primary and
the secondary tumor (T ) lesions in the liver receive their blood
supply primarily from the hepatic artery, whereas non-tumoral
liver (NL) is almost excluded from the hepatic artery and fed
essentially via the portal vein. Spheres are injected in the hepatic
artery and become trapped within the T microvasculature, so that
they selectively deliver radiation to the T whilst sparing normal
tissue. In NL, microspheres remain confined to the portal tracts
(1). This locoregional technique represents a good option to irra-
diate liver T as compared to external beam radiation therapy
(EBRT), this latter being limited by the high radiosensitivity of
the liver parenchyma. A further advantage of RE is that it can be
combined with other therapy modalities that are under study in
several phase III multicentre trials (2). Two types of microspheres
are commercially available, the glass spheres [Therasphere® BTG,
Ontario, Canada (3)] and the resin spheres (SIR-Spheres®, SIR-
Tex Medical Limited Sydney, Australia, http://www.sirtex.com)
(4). The activity to be administered is chosen using empirical or
raw dosimetric methods, depending on the types of spheres, while
fully dosimetric treatment planning is very rarely applied. Over-
all, significant response rates have been observed in patients with
unresectable primary or secondary hepatic malignancies, with a
limited number of side effects (5–8). However, no study was specif-
ically accomplished to enlighten the power of a fully dosimetric
treatment planning: increased efficacy and reduced toxicity. In
nuclear medicine treatment, the importance of dosimetry to com-
prehend the radiobiological effects is growing and documented
by the increased number of papers addressing dosimetry in the
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recent literature (9–13). In RE, the essential dosimetry methods
based on compartmental models have been more traditionally
applied and have proved correlations between absorbed doses and
effects. Even if still in few centers, dosimetry planning guides RE
treatment (13–15). Specific experimental studies and mathemati-
cal modeling at the microscopic level have provided enlightening
information for the understanding of macroscopic observations,
such as the RE-induced liver disease (REILD) and the different
behavior of glass versus resin spheres, with the apparent higher
tolerability of RE with glass spheres and higher absorbed doses
associated to T response (12–14, 16). More recently, 3D voxel
dosimetry methods have been applied to RE, providing dose distri-
bution maps and dose–volume histograms (DVH). This allowed to
apply radiobiological models to predict the probability of toxicity,
normal tissue complication probability (NTCP), and T response,
tumor control probability (TCP). In regard to the clinical context,
outcomes such as the volume effect, the influence of the functional
reserve and/or concomitant therapies, with higher tolerability of
re-treatment, reflect a further similarity with EBRT, which can be
identified as a foremost reference to compare with, although dif-
ferences with EBRT exist and must be considered. The aim of this
study is to comprehensively review the literature addressing these
issues from a radiobiological perspective.
TWO TYPES OF 90Y-MICROSPHERES
90Y is a pure β-emitter radionuclide with maximum and average
β-energies of 2.28 MeV and 934 keV, respectively, corresponding
to a maximum and average path lengths in soft tissue of 11 and
4.1 mm, respectively. It has a half-life of 64.2 h and it decays into
the stable element 90Zr. There is also a minor branch of the decay
to a O+ first excited state of 89Zr at 1.78 MeV, which is followed
by a β+ β-emission. Although the branching ratio is very low
(32× 10−6), it is most important as it allows 90Y-microspheres
PET imaging after RE (17, 18). The release of the absorbed dose
occurs in the surrounding tissue according to the 90Y-range.
The main characteristics of glass and resin spheres are sum-
marized in Table 1. Microspheres are biocompatible but not
biodegradable or metabolized. The most relevant difference
between the two types of spheres is the activity per sphere, which
is much higher in the glass spheres (~2500 Bq) than in resin ones
(~50 Bq) (see also section Activity Distribution at the Micro-
scopic Level). A further difference between resin and glass is
the shelf-life, being 1 day for resin spheres, and 12 days for glass
spheres. This implies that the same number of resin spheres/GBq
is always injected, while the number of glass spheres/GBq increases
according to 90Y physical decay (time interval left between prepa-
ration and administration). Overall, for a same activity, the ratio
between the number of resin and glass spheres can vary from 50
(2500 Bq/50 Bq) to 2.2 [2500 Bq/(22.6× 50) Bq]. This point has
interesting dosimetric consequences that will be described later
on (section Activity Distribution at the Microscopic Level).
Flow stasis, making the injection of the whole planned activity
impossible, has been observed during resin microspheres adminis-
tration (especially in super-selective treatments), while it has never
been reported with glass microspheres (19, 20). This is probably
due to the very high number of particles, and suggests a possible
role of embolization in the case of resin spheres (see also section
Activity Distribution at the Microscopic Level).
ADMINISTERED ACTIVITY
The amount of activity to be administered should ideally be estab-
lished accounting for the major factors that may influence therapy
Table 1 | Characteristics of 90Y-microspheres (6, 20, 24).
Commercial name SIR-Spheres® TheraSphere®
Manufacturer Sirtex Medical, Lane Cove Australia Therasphere BTG, Ontario, Canada
Material Resin Glass
90Y sphere production Bound to resin, attached to sphere surface Embedded in a glass matrix
Particle size (µm) 32.5±2.5 (range: 20–60) 25±5 (range: 20–30)
Activity per sphere (Bq) 50 (range: 40–80) 2500 at the reference time
Number of spheres per GBq (million) 20 (mean) 0.4 at the reference time
Shelf-life 1 day 12 days
Specific gravity Low (1.6 g/cc) High (3.6 g/cc)
Embolic effect Moderate Mild
Activity available (GBq) 3 From 3 to 20, with step 0.5
Number of spheres in 3GBq 40–80 million 1.2 million at the time of calibration
Approved for USA: HCC; Outside USA (especially Europe
and Australia): unresectable liver tumors
(HCC and metastases)
USA: colorectal carcinoma Outside
USA (especially Europe and Australia):
HCC and metastases
Handling for dispensing Required Not possible
Splitting one vial for two or more administrations Possible Not possible
Necessity of contrast medium guidance during administration Yes No
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outcome. Among these, there are the NL involvement, the tumor
uptake, the possible side effects to healthy tissues, the baseline
patients’condition, and the absorbed dose. More rarely, the activity
to be injected is based on dosimetric evaluations (13–15, 21, 22).
Table 2 summarizes the methods proposed, equations, constraints,
and essential pros and cons for the two types of microspheres.
For resin microspheres, three methods (i, ii, and iii) have been
suggested by the manufacturer (4) to decide the 90Y activity. In
common, they have the indication of reducing the prescribed
activity depending on the lung shunt (LS) fraction, in order to
lower the radiation risks to the lungs.
(i) The empirical method recommends three different activities
based on T involvement (Table 2). It is not an individual-
ized approach because it does not account for the volume of
the NL involved in the irradiation, and thus its tolerability.
It is worth noting that with the highest activity, the absorbed
doses to the lungs and to NL are within ~18 and ~83 Gy,
as derived using the OLINDA/EXM software for a standard
patient (23). Note that among 28 patients dead at least in part
because of liver toxicity over 680 treated with resin spheres,
21 from a single center were administered according to this
method (24).
(ii) The body surface area (BSA) method, still empirical, takes
into account the patient’s BSA, the T mass (MT) and the
NL mass (MNL), assuming a correlation between BSA and T.
However, there is experimental evidence that the BSA does
not correlate with ML or with T involvement (25). Even if it
includes some individual parameters, it should not be mis-
construed in terms of tailored evaluation, as it neglects the
individual T /NL avidity ratio, which is patient specific, even
lesion specific (22). Activities remain usually within 2.5 GBq
(25). This is the method most commonly used for RE with
resin spheres (24).
(iii) The multi-compartmental MIRD macrodosimetry method
(also known as partition model) (26, 27) calculates the activ-
ity to be administered using the MIRD equations, once an
absorbed dose limit is prescribed to NL, but no liver toxi-
city nor efficacy threshold accompanied this methodology.
The lung safety is also considered, with a specific absorbed
Table 2 | Methods to determine the activity to be injected according to device user manual.
Sphere
type
Model and
references
A (GBq) Notes
General cases Special constraints
Resin (i) Empirical (4, 24) In case of LS<10% Activities lowered by 20% if
LS=10–15%;
40% in case LS=15–20%;
treatment avoided if LS>20%
Empirical; not personalized for different liver
size nor for tumor and liver perfusion; based
on whole liver infusion
2.0 if tumor involvement≤25%
2.5 if tumor involvement 25–50%
3.0 if tumor involvement>25–50
(ii) BSA (4, 24) In case of LS<10%
A = (BSA− 0.2)+ MT
MT +MNL
Activities lowered by 20% if LS
10–15%;
40% if LS 15–20%;
No treatment if LS>20%
Empirical; the most commonly applied;
heritage from chemotherapy; not actual
personalization; individual tumor and
parenchyma perfusion not accounted; more
conservative than empirical method; based
on whole liver infusion; prescription
empirically reduced for safer approach
(iii) Partition or multi-
compartmental
method (4, 15, 26,
27)
A = DNL × T/NL ·MT +MNL50 · (1− LS)
with T/NL = AT
MT
/
ANL
MNL
Activities lowered by
20% if LS 10–15%;
40%ifLS 15–20%;
No treatment if LS>20%;
DNL=80 Gy; 70 Gy if cirrhosis
D lungs <25 Gy, preferably 20 Gy
Personalized, accounts for tumor avidity and
liver involvement; based on whole liver
infusion, originally designed for single or
discrete nodules, appropriate modification by
makes it applicable to multiple lesions
Glass (iv) Monocom-
partmental MIRD
(partitional) (3, 28)
A = DM ×M
50(1− LS) Constraint DM to the whole tissue
treated, typically 80–150 Gy, and
constraint of D lungs (typically
20–30 Gy) <10% shunt
Not really personalized, it does not
discriminate for different tumor avidity and
involvement; applicable to whole liver, lobar,
and segmental infusion
A, activity (GBq); LS, lung shunt fraction; BSA, body surface area; A, activity to be administered (GBq); MT, tumor mass (kg); NL, non-tumoral liver; T, tumor; MNL, NL
mass (kg); AT,T uptake (GBq); ANL, NL uptake (GBq);T/NL,T over NL uptake ratio; DNL, absorbed dose limit prescribed for NL (Gy); Dlungs, absorbed dose limit prescribed
for the lungs (Gy); 50, conversion factor (Gy × kg/GBq) for 90Y for a standard patient; M, whole mass (MNL +MT) (kg); DM, absorbed dose limit prescribed for M.
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dose constraint. The equation takes into account the T /NL
uptake ratio, the liver involvement (MT and MNL) and the
possible LS.
One single method is proposed for glass spheres by the
manufacturer:
(iv) The mono-compartmental MIRD macrodosimetry model
relies on a simplified dosimetry equation of the multi-
compartmental model (3, 7, 28) in which an absorbed
dose to the whole liver or lobe (DM) – typically ranging
from 80 to 150 Gy – is empirically prescribed as averaged
on the whole treated liver or lobe, including the T, of
mass M =MT+MNL. So, a uniform activity distribution
is assumed and absorbed doses to T and NL are not sepa-
rately calculated. No distinction is made for different tumor
involvement and avidity.
The methods (i), (ii), and (iv) are appealing for their simplicity
but clearly suboptimal. This has led to possible under-treatments,
compromising efficacy, or over-treatments, inducing unwanted
effects. The multi-compartmental dosimetric model (iii) provides
a more scientifically sound basis for the activity determination,
although it demands a confident identification of absorbed doses
ensuring liver tolerability. Moreover, it relies on the possibility to
simulate therapy.
SIMULATION OF THE TREATMENT
The therapy session is generally simulated with intra-arterial
administration of 99mTc-MacroAggregate Albumin (99mTc-MAA)
that should mimic the vascular distribution pattern of 90Y-
microspheres. The simulation is mandatory to evaluate the possi-
ble LS fraction and to exclude gastrointestinal (GI) shunt. 99mTc-
MAA is also used to analyze, at least visually (29), the T /NL
uptake ratio and to evaluate dosimetry in the frame of individ-
ualized treatment planning. This is based on the hypothesis that
99mTc-MAA and 90Y-microspheres have identical intra-hepatic
distribution, due to comparable size (10–100µm diameter) and
density (12, 26). However, the adequacy of this hypothesis is
under debate, since the number/dimension of injected resin, glass,
and MAA particles differ. The number of injected resin spheres
greatly differ, being ~300 times higher than the number of 99mTc-
MAA particles and ~50 times higher than the number of glass
spheres (12). Thus, a possible higher embolic effect of resin spheres
is expected as compared to glass spheres, versus no significant
embolic effect of MAA particles on the hepatic arterial circula-
tion. Other differences may rise from different micro-catheter tip
placement and regional blood flow changes between simulation
and RE. These points have created concern about the predic-
tive value of 99mTc-MAA scintigraphy for NL and T dosimetry.
Results from the literature are controversial. Wondergem et al.
(30) found discrepancies between 99mTc-MAA images simulating
RE and 90Y-Bremsstrahulg SPECT images – post-RE – in patients
with a mismatch in catheter tip positioning during administra-
tions. This study highlights the importance of this maneuver when
using MAA images as predictive of microsphere distribution. Kne-
saurek et al. (31) found poor correlation in some of the patients
analyzed. The same group confirmed the critical role of catheter
repositioning in combination with proximity to an arterial bifur-
cation (32). In a study object of discussion, Ulrich et al. claimed
a low predictivity of MAA based on visual examination of MAA
and 90Y-Bremsstrahulg SPECT images (29, 33). On the other hand,
despite undeniable differences, the significance of 99mTc-MAA in
the treatment planning of resin spheres has been shown (14, 33,
34). Strigari et al. (16) stated that 99mTc-MAA SPECT images of
the abdomen were sufficiently predictive of the 90Y-SIR sphere dis-
tribution in more than 80% of patients. Flamen et al. (35) reported
that MAA and 90Y imaging did correspond in all cases.
For glass spheres, the problem is less evident, thanks to the lower
number of injected particles. The capability of MAA based lesion
dosimetry to predict response and even overall survival (OS) has
been shown (14), meaning that in the majority of patients the
simulation is worthwhile (33). Chiesa et al. (12) compared 99mTc-
MAA and 90Y-SPECT in 35 patients treated with glass spheres.
In 71% of cases, distributions were similar. In 8/35 patients, dif-
ferences were marked, and uncertain in 6%. Discrepancies were
attributed mostly to intentional changes in catheter positioning,
while in 2 patients (6%) to the different specific weight of glass
microspheres with respect to MAA. Kao et al. (36) retrospectively
analyzed 99mTc-MAA-SPECT and 90Y-PET images, and compared
the mean T absorbed doses. Excellent correlation was found
in selected patients, with a relative error ranging from −1.2%
to +13.2%. Preliminary results from direct DVH comparison
between 99mTc-MAA-SPECT and 90Y-PET have been presented to
assess the role of treatment planning based on simulation images
(37, 38). Several authors showed a good correlation between the
T absorbed dose based on the partition model and the response
to 90Y-microspheres in metastatic disease, as well as in HCC (12,
14, 22, 35, 39–41). In particular, Garin et al. (14) have shown
that dosimetry based on 99mTc-MAA-SPECT not only predicts T
response but also OS in patients with HCC. 99mTc-MAA scintig-
raphy is a relevant source of information for patient recruitment
and RE treatment feasibility. Provided that both the tracer and
microspheres are injected under the same condition, 99mTc-MAA
SPECT-CT gives an accurate description of the microspheres dis-
tribution in T, as well as in normal tissues, predicting the shunt to
extra-hepatic lungs and the GI tract (36, 42, 43).
VERIFICATION OF THE TREATMENT
The evaluation of the actual biodistribution in RE is of utmost
importance in order to verify the 99mTc-MAA prediction. A first
option is to acquire Bremsstrahlung-SPECT images (12, 16, 43,
44), although difficulties raise from the poor-quality images that
could lead to inaccurate quantification of microsphere biodis-
tribution. Some authors have shown the possibility to obtain
impressive imaging improvements by applying appropriate cor-
rections for scatter, attenuation, and response of the system (45,
46) or a special collimator (47), but the suggested methods are
applied only in very few research centers since they require very
careful calibration and experience. Alternatively, Lhommel et al.
(17), followed by other authors (18, 48–50), have shown that
PET/CT scanners are able to provide good-quality 90Y images
when radioactivity is highly concentrated, as in RE, and that accu-
rate patient dosimetry is attainable. A further step is represented
by the 3D analysis at the voxel level. Several authors have elab-
orated pre-treatment 99mTc-MAA-SPECT and/or post-treatment
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90Y-PET images (35, 36, 49–52) identifying the heterogeneity of
the activity distribution at the spatial resolution of SPECT or PET.
Recent studies have applied the voxel dosimetry to 90Y-PET images
to obtain dose distribution maps and DVH (36, 37, 49, 50, 53).
These methods, which recall those used in EBRT, could improve
dose–effect correlations and identify appropriate radiobiological
models.
ACTIVITY DISTRIBUTION AT THE MICROSCOPIC LEVEL
The standard dosimetry at the organ level assumes uniform activ-
ity in tissues and considers only marginally patient-specific varia-
tions. Based on 3D image analysis, the heterogeneity of the activity
distribution can be assessed at the spatial resolution of SPECT or
PET, which remains, however, at the macroscopic level (35, 36,
49, 51–54). To assess the heterogeneity at the microscopic level,
and more deeply understand the radiobiological mechanisms,
some authors analyzed the particle distribution of explanted livers
(55, 56). Other studies have elaborated mathematical simulations
of the hepatic structures to derive the dosimetry at the micro-
scopic scale. This paragraph focuses on the main issues of these
studies.
Fox et al. (55) were the first to introduce the basic argument
of the non-uniformity of dose distribution at microscopic level,
studying the microsphere positions in an explanted treated liver.
They found that dose distribution around a microsphere exhibits
an extreme dose gradient of more than 5 orders of magnitude
in 2 mm and thus the non-uniformity of dose deposition spares
regions of parenchyma, increasing its tolerance with respect to
EBRT.
Yorke et al. (57) applied a parallel model introducing a micro-
scopic lobule model to account for non-uniform dose deposition
at microscopic level and explain the lack of liver complications
with liver absorbed doses up to 150 Gy (58). Dose-rate effects were
also introduced and variable values of the enzymatic halftime of
sub-lethal damage repair (T rep= 0.5, 1, 1.5, 2 h) were considered.
Interestingly, TD5 and TD50 values increased by more than 50 Gy
compared to the uniform dose distribution, confirming the impact
of non-uniformity.
Ten years later, Kennedy et al. (56), provided the pathologic
hepatic findings in four explanted livers, performing dosimetry
on a microscopic scale in a T irradiated with glass microspheres.
The authors found a preferential and heterogeneous deposition of
microspheres at the edge of T nodules compared with the center
of the tumor or NL, with a ratio from 3:1 to 20:1. The conse-
quence is a selective radiation delivery to the T /NL edge. Resin
and glass microspheres showed similar distribution in NL, whilst
a higher number of resin spheres tended to cluster at the edge of
the T nodules. This was imputed to different number of resin and
glass spheres administered and to higher specific activity of glass
spheres. No veno-occlusive disease (VOD) or radiation hepatitis
but only slight radiation effect was observed in NL parenchyma
far from the tumors (over the range of the β particles). 3D dose
calculations showed that both glass and resin microspheres deliver
heterogeneous absorbed doses to the tumor (ranging from 100 Gy
to more than 3000 Gy). A rapid dose falloff from 300 to 100 Gy
within 4 mm was reported. The two cases of colon metastases
showed at least 90% necrosis in all tumor nodules. Overall, the
findings confirmed that both liver tumor (HCC and metastases)
are preferentially vascularized by the hepatic artery and that the
vasculature is crucial for the efficacy of RE. Vessel density is hetero-
geneous within the liver and the T (6), as the activity distribution,
and therefore less effective than in EBRT.
In the paper by Gulec et al. (1),a 3D hexagonal liver model based
on lobular microanatomy was developed, and the microscopic
absorbed dose distribution was calculated in various components
of the NL structure by Monte Carlo code. Spheres in NL are
entrapped within the terminal arterioles/portal tracts at the edges
of each lobule, which have diameters comparable to those of the
microspheres (30µm). The model represented this pattern consid-
ering a hepatic lattice of lobules and the corresponding vascularity,
with the portal tract (hepatic artery, portal vein, and bile duct),
and the central vein at the center of each lobule. A uniform lin-
ear distribution of the microspheres was reproduced within the
hepatic artery (no clustering was simulated), with different sce-
narios including 50 Bq/sphere (resin) and 2500 Bq/sphere (glass).
Evaluations according to the macroscopic compartmental model
based on MIRD equations were also performed for comparison
purposes. The results revealed that average parenchymal and cen-
tral vein absorbed doses were similar to the average NL absorbed
dose of the compartmental model, while the portal tracts received
significantly higher absorbed doses. For a single sphere, the central
vein received approximately ~6% of the absorbed dose received by
the portal tract, compensated by the cross-fire effect to a fraction
of ~50%. The major difference observed between the two types
of spheres was that for resin spheres, the absorbed dose to portal
tract was more than twofold the absorbed dose to the NL, whilst
for glass microspheres, the absorbed dose to portal tract could be
slightly lower or more than threefold the liver absorbed dose, with
marked non-uniformity in portal tracts for glass spheres. Further-
more, it was shown that a significant cross-fire effect increases the
absorbed dose to the hepatocellular parenchyma and the central
vein. The authors concluded that there was a consistent relation-
ship between the average liver dose as from MIRD macrodosimetry
and the microscopic dosimetry estimates. This study validates the
clinical utility of the MIRD methodology in the accurate estima-
tion of the absorbed doses to the central vein and parenchyma, but
not to the portal tracts. These results are compatible with REILD,
as defined by Sangro et al. (1, 59) (see section Side effects to the
liver). A strongly non-uniform absorbed dose distribution in por-
tal tracts for glass microspheres is in agreement with the observed
higher tolerance.
Another model assessing microscale dosimetry was applied
recently by Walrand et al. (60) to explain the apparent para-
dox of higher liver tolerance to glass (13) as compared to resin
spheres (16). Assuming a random microsphere trapping in the
portal tracts combined to the different number of spheres, the
authors calculated a non-uniform absorbed dose distribution in
order to justify the above discrepancies. The same liver model
by Gulec et al. (1) was considered, but symmetric and asymmet-
ric branching probabilities of the microspheres were considered
at each vessel bifurcation. Simulations were performed leading
to absorbed doses of 120 and 40 Gy to the liver for glass and
resin microspheres, respectively. The results showed that for a 60–
40% branching probability, the fraction of portal tracts without
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trapped glass microsphere increased, and the lobular dose dis-
tribution of glass spheres became strongly asymmetric, with a
maximum value of 50 Gy (as compared to 103 Gy of a symmetric
spreading). Most importantly, the dose distribution of the portal
triads (the critical tissue in RE) of the glass spheres was similar
to that of resin microspheres despite a threefold mean absorbed
dose difference to the liver. Therefore, the model justifies that the
liver tolerance raises from 40 Gy for resin spheres to 120 Gy for
glass spheres.
Another interesting point raised by Walrand et al. (60) regards
the embolization effect of the portal tracts by the resin micros-
pheres. Without accounting for embolization, a higher number
of lobules had at least a portal triad receiving <40 Gy as com-
pared to the case in which embolization was considered: the effect
was to redirect a part of the resin microspheres to portal tracts of
lower initial trapping probability. Embolization reduces the non-
uniformity of the resin microsphere distribution among portal
tracts and increases the number of portal tracts receiving more
than 40 Gy, with a potentially more toxic treatment. In the clinical
applications, the role of embolization with resin spheres is still to
be clarified, as controversial results have been published, with a
trend toward improved OS of patients with the stasis phenome-
non (61), in contrast to only mild inflammation of animal tissues
embolized with non-radioactive resin microspheres (62).
Comparing clinical findings with the two kinds of devices,
Chiesa et al. (2, 12) suggested that for a fixed mean absorbed dose,
the higher the number of particles/GBq, the higher the biological
effect. The study by Walrand et al. microscopically interpreted this
phenomenon for normal tissue. The distribution at the micro-
scopic scale varies with the number of particles/GBq, increasing
toxicity and efficacy, thus new safe mean absorbed doses should be
derived (lower with increasing the number of particles) based on
future clinical studies. Lewandowski et al. (63) recently reported a
study exploring the possible benefits of a “delayed” (an extended
shelf-life) treatment with higher number of glass spheres/Gy. In
particular, a time shift providing a double number of glass spheres
compared to the reference date was considered, keeping the same
standard absorbed dose (123 Gy). The authors hypothesized that
increasing the number of glass microspheres, a better tumor dis-
tribution would occur without additional adverse events. They
concluded that this methodology was safe with promising response
rate. However, a better understanding of the potential and risk of
this approach needs a more systematic comparison among patients
having similar clinical status and pathology. Moreover, tumor and
NL averaged absorbed dose should be calculated to better clar-
ify the safety and efficacy. Finally, keeping the same rationale of
120 Gy to the lobe should be regarded with caution, being a sort
of absorbed dose-escalation study at the microscopic level (espe-
cially to the portal tracts), because a higher NL absorbed dose
could overcome the threshold for side effects.
RADIOBIOLOGICAL MODELING
The linear quadratic model (LQM) has been used to describe the
radiobiological effects in several radionuclide therapies and details
can be found in reference (11). More relevant definitions also
used in EBRT are introduced. The biological effective dose (BED)
is widely used to assess the effect of absorbed doses, uniformly
delivered in a few minutes in multiple fractions in EBRT. The BED
accounts not only for the absorbed dose but also for the dose
rate, when assessing the tissue response to the radiation injury.
More recently, the LQM has been reformulated to model therapies
with continuously variable dose rate, and possibly non-uniform
absorbed dose distribution, such as RE. Thus, for two different
radiation modalities with the same BED, the same biological effect
is expected to occur, provided to be able to evaluate the BED with
enough accuracy.
The principal equations of the radiobiological method are here
summarized:
ln (SF) = −α BED (1)
for EBRT: BED = DEBRT
(
1+ DEBRT/N
α / β
)
(2)
for RE: BED = DRE
(
1+ DRE · λ eff(
µrep + λ eff
) · α / β
)
or DRE
(
1+ DRE · Trep(
Trep + Teff
) · α / β
)
(3)
where SF is the fraction of cells surviving after irradiation, α/β
gives the curvature of the survival curve and relates the intrin-
sic radiosensitivity α and the potential sparing capacity (β),
DEBRT is the absorbed dose delivered with EBRT in N fractions
(absorbed dose per fraction: DEBRT/N ), DRE is the absorbed dose
delivered with RE, λeff is the effective rate constant of a mono-
exponential variation of the absorbed dose rate, as applies in RE,
which accounts for a protracted radiation where repair of sub-
lethal DNA damage can occur (in RE, λeff equals the physical
decay constant of 90Y: λeff =λphys= 0.0108/h), µ is a mono-
exponential repair constant of a single DNA strand damage, and
T eff (T eff =T phys= 64.2 h) and T rep are the halftimes for 90Y
decay and repair damage.
The radiobiological parameters included in Eqs 1–3 are spe-
cific for the tissues and the effects (typically, α/β is assumed to be
2.5 Gy for the normal tissue and 10 Gy for the T. T rep= 2.5 h for
NL (µrep= 0.28/h), 1.5 h for T (µrep= 0.53/h)).
In case of spatial absorbed dose non-uniformity, the equivalent
uniform BED (EUBED) has been used for T and organs with par-
allel structure to represent the uniform biological absorbed dose,
which would produce the same number of surviving cells (64).
It can be calculated to assess the possible radiobiological effect,
according to the following equation:
EUBED = − 1
α
ln (SF) = − 1
α
ln
 ∞∫
0
P (BED) · e−α·BEDdBED

(4)
where P(BED) represents the probability density function of BED,
and exp(−αBED) expresses the fraction of surviving cells SF. This
applies in case of T or in case of functional subunits of parallel
organs, as the liver and the lungs (10, 65).
In some cases of RE, also the equivalent uniform dose (EUD)
can be a useful parameter. It represents the absorbed dose given
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uniformly that will lead to the same effect as the actual non-
uniform absorbed dose distribution, and can be extrapolated by
solving the following equation:
EUBEDRE = EUDRE
(
1+ λ
(µ+ λ) · α/βEUDRE
)
(5)
This equation mirrors Eq 3 but accounts for non-uniformity.
Similarly, EUD for EBRT can be derived as the solution of:
EUBEDEBRT = EUDEBRT
(
1+ EUDEBRT
N · α/β
)
(6)
Concerning the risk of toxicity, the phenomenological curves of
NTCP (66) derived from the EBRT experience can be considered.
The expression proposed to fit the EBRT absorbed dose–response
data for a uniform irradiation of the whole organ is:
NTCP = 1√
2pi
t∫
−∞
exp
(
−x
2
2
)
dx (7)
with t = D − TD50,5
m · TD50,5 , (8)
where D is the total absorbed dose, m is a parameter repre-
senting the steepness of the dose–effect curve, and TD50,5 is the
absorbed dose value for which 50% of the population exhib-
ited complications within 5 years for a uniform whole-organ
irradiation.
An alternative definition of EUD was proposed in EBRT. When
the organ is irradiated with a non-uniform absorbed dose dis-
tribution, with fractions of volumes v i uniformly irradiated with
an absorbed dose Di (identifying the series {v i, Di}), the effective
volume method is applied in EBRT for reducing the DVH data
to the unique parameter EUD (67). The NTCP associated to the
non-uniform absorbed dose distribution can thus be calculated
from Eqs 7 and 8 assuming that the whole organ is uniformly irra-
diated with an absorbed dose equal to EUD. The parameter EUD
is defined as:
EUD =
(∑
i
D
1
n
i vi
)n
(9)
where n is the volume-effect parameter (e.g., n= 0 for serial
organs, 0< n< 1 for serial-parallel organs).
In order to apply the same model in case of an hypotheti-
cal uniform RE irradiation, the BED values from RE need to be
converted into the equivalent dose at 2 Gy/fraction (EQD2), the
standard treatment of EBRT, according to Eq 10:
EQD2 = BEDRE · α/β
2+ α/β (10)
Similarly, in case of non-uniformity, the {vi, BEDi} series
derived from molecular radio-therapy (MRT) can be converted
into a series {(v i, EQDi)}, which are the input for Eq 9 to derive
EUD, and then apply Eqs 7 and 8.
As regardsT, a generalized expression of BED includes the effect
of repopulation that occurs during treatment and wasting some
of the delivered absorbed dose (68). Considering an exponen-
tial clonogen proliferation with doubling time T av and a time of
treatment T, the Eq. 3 becomes:
BEDtumor = DRE
(
1+ DRE · Trep(
Trep + Teff
) · α/β
)
− ln 2
αTav
T (11)
Finally, for a certainT BED (or EUBED in case of non-uniform
absorbed dose distribution), the TCP is defined (69) for an initial
number of clonogenic cells N 0 as:
TCP = exp (−N0 · SF) = exp
(−N0 · exp (−α · BED)) (12)
COMPARING RE AND EBRT
Few models of TCP and NTCP have been reported in literature
that are able to predict the clinical outcome of EBRT, confirming
that a correlation is possible when based on the LQM. Consid-
ering the BED concept as possible rationale for RE planning,
the equations of the previous paragraph are the simplest way to
convert the absorbed doses from RE to EBRT, and vice versa. More-
over, it is possible to follow the EBRT imprint, comprising DVH,
dose–volume reduction, EUBED, and/or EUD evaluations. This
conversion could allow to derive estimates of prescribed limits to
fulfill in RE based on EBRT studies, such as the effects of single
lobe (or segment) versus whole liver irradiation, and the possi-
ble consequences of concurrent chemotherapy or re-treatment
(15). However, the problem is complex due to the liver struc-
ture and the different irradiation conditions. Two different end
points are under study, since in EBRT the centrilobular vein is the
critical target, while in RE the portal tracts have different irradia-
tion mechanism. Moreover, RE deeply differ if using glass rather
than resin microspheres, as described in Section “Side effects to
the liver.” From this point, the irradiation conditions of resin
spheres are more similar to EBRT, resulting in more uniform dose
deposition.
A purely mathematical example of tolerance doses derived
from EBRT is reported in Table 3 assuming uniform dose dis-
tribution to the liver and lungs. This could be taken as starting
point for proper phase I absorbed dose-escalation studies, which
were never done. The following table was extrapolated using a
set of radiobiological parameters taken from EBRT, while this
applicability should be experimentally confirmed for RE. It is not
directly applicable to glass microspheres. For whole liver irradi-
ation, the same biological effect caused by an absorbed dose of
30 Gy (TD5/5) with EBRT could correspond to a BED of 54 Gy
and to an absorbed dose of 35 Gy uniformly released by resin
sphere RE.
A second aspect is that smaller volumes of a “parallel organ”
(e.g., liver or lungs) can tolerate higher absorbed doses (volume
effect). In fact, Emami et al. (70) derived tolerance values pro-
ducing a risk of 5% for partial irradiation of the liver, resulting
in 35 and 50 Gy for an irradiation volume equal to 2/3 and 1/3
of the whole organ, respectively. This suggests that lobar or seg-
mental RE treatments can deliver higher absorbed doses when
compared to absorbed doses delivered to the whole liver. Moreover,
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Table 3 | Mathematical example of tolerance doses derived from EBRT assuming a uniform dose distribution to liver and lungs.
Treated
volume
TD5/5 (Gy)
EBRT
TD50/5 (Gy)
EBRT
BED5/5 (Gy)
EBRT=RE
BED50/5 (Gy)
EBRT=RE
D5/5 (Gy)
RE
D50/5 (Gy)
RE
Liver 3/3 30 40 54 72 35 44
2/3 35 45 63 81 40 47
1/3 50 55 90 99 51 55
Lungs 3/3 17.5 24.5 29 41 23 30
2/3 30 40 50 67 35 43
1/3 45 65 75 108 47 62
Liver absorbed doses from EBRT (70) converted to BED (values are the same EBRT and RE) and extrapolated for RE assuming α/ β=2.5 Gy (liver), 3 Gy (lungs),
Trep =2.5 h.
the lower NL is the volume treated, the higher is the tolerability.
According to Dawson et al., irradiating less than 25% of the liver
volume allows whichever dosage (71). This was clinically verified
by Rhee et al. in super-selective treatment with glass spheres with a
median dose of 348 Gy to liver segment (72). RE with resin spheres
involving only the right lobe or the left lobe could be roughly com-
pared to an EBRT irradiation of 2/3 and 1/3 of the whole liver,
respectively.
A third issue is represented by the different tolerance accord-
ing to the basal liver status (liver function). Unfortunately, it is
rare that a patient is planned for RE without previous treatments
or underlying disease. Metastatic patients planned for RE usu-
ally have already received chemotherapy, while HCC is usually
superimposed to liver chyrrosis. Patients naïve to RE or with a
better liver status should have a higher tolerability as compared
to patients after several chemotherapy treatments or with under-
lying disease. The EBRT experience shows different NTCP curves
according to different basal status (73). This has been observed to
apply also to RE clinical experience (59). A more detailed compar-
ison of EBRT data can be found in the review of Chiesa et al. (12).
After RE with glass spheres, the same group reported an increased
liver decompensation rate according to the worsening of Basal
Child (13).
A fourth issue concerns the cases of re-treatment. In EBRT,
the cumulative absorbed dose to the well-known limits for tox-
icity. On the contrary, the literature reports several examples of
re-treatment in RE, where dose limits were applied to each single
administration, but that were overcome cumulatively. Both pro-
ducer’s indications do not mention the problem of re-treatment,
meaning that the same BSA or 120 Gy prescription could be
applied repeatedly. This could explain the toxicity reported by
some authors after multiple RE treatments (53, 74). The prob-
lem of safety re-treatment lacks of specific published data. From
the radiobiological point of view, multiple administrations with
reduced parenchyma adsorbed dose (e.g., 2× 20 Gy) theoretically
result in lower BED, i.e., in lower toxicity, than a higher single
dose of 40 Gy in a single administration (15). This aspect can be
explained by using LQM and dose-rate effect, well known in EBRT
and in some radionuclide therapies (10, 11). The cost–benefit ratio
of this argument deserves attention and clinical validation and
should consider the life expectancy of patients and the complexity
of repeated intra-arterial administrations.
DOSE–EFFECTS CORRELATIONS
The present section proposes a comprehensive overview of the
literature as regards the possible correlations between absorbed
doses and radiation-induced effects, on normal tissues and T.
SIDE EFFECTS
The principal risks associated to RE are due to an excessive irra-
diation to NL and to an extra-hepatic shunt (observed in a low
percentage of patients). If an extra-hepatic shunt exists, relevant
toxicities, such as radiation pneumonitis, gastric/duodenal ulcer-
ation, and radiation cholecystitis can occur (5). LS is observed
especially in HCC patients, who need quantitative evaluation of
activity driven to lungs. Gastroduodenal complications occur in
less than 5% of cases and can be prevented by careful evaluation of
99mTc-MAA-SPECT images. A potential risk of red marrow irra-
diation related to possible free 90Y is due to its natural tropism for
the bone. About hematological toxicity, the review of Riaz et al. (5)
indicates ~25% lymphocytes reduction in the majority of treated
patients. G3 or G4 lymphopenia was reported by Mazzaferro et al.
(75) and by Hilgard et al. (76) in ~10% of HCC patients, but the
exact origin is still unclear.
To date, the risk of complications induced by RE is accept-
able when patients are adequately selected and the procedure
of microsphere injection is carefully operated. Nevertheless,
threshold absorbed doses avoiding toxicity are still not defi-
nitely identified, being neither dosimetry nor NTCP modeling
systematically applied, or properly reported. For instance, the
studies on glass spheres have usually provided absorbed dose
values averaged on the injected portion of liver (without dif-
ferentiating between NL and T ), losing the information about
the actual tolerability of the liver parenchyma and of the irra-
diation required to control the tumor. Using BSA method with
resin spheres, the absorbed doses to NL vary in a wide range
[median 36 Gy, range: 6–78 Gy (16)]. Moreover, an average dose
that assumes uniform activity does not reflect the actual micros-
phere distribution (36). These drawbacks have been recently high-
lighted and works reporting dosimetry information, as well as
the quality of dosimetric evaluation, has consistently increased.
Studies at the microscopic level have offered complementary
information that allow to better interpret the experimental find-
ings [(1, 56, 60); section Activity Distribution at the Microscopic
Level].
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FIGURE 1 | Liver absorbed doses (Gy) and tolerability. The graph shows
the liver absorbed doses (Gy) reported in the literature with information about
the associated liver tolerability. Red bars represent liver toxicity with fatal
event (death); orange bars represent the threshold for observed toxicity or the
limit recommended by the author; green bars represent tolerated absorbed
doses. References are reported in parenthesis after the name of the first
author. t., treatment; *(77) patient with previous EBRT (21 Gy) and RE with
71 Gy, ∧∧(42) recommendation based on a review of the literature, ∧(59)
primary+mets, WL treatment, **(78) primary+mets, WL treatment,+ (16)
HCC, WL (48%) and L (52%), mean dose to WL for REILD>G1: 6–78 Gy. The
bar represents the median value of the interval (36 Gy), ++(22) WL
treatment,°(79) O-I, HCC, multiple treatments, §§(80) HCC, segmental
treatments, - -(81) HCC, WL, and lobar treatments. No use of REILD toxicity
score, +++(82) HCC, 9 O-I, 11 O-II, no distinction between tumor and NL
dose, -(54) mean NL dose=58 Gy, §(83) patient receiving RE to the right lobe
(139 Gy) and the left lobe (158 Gy). The bar represents the mean value
between the right and left lobe, ***(77) patient with previous EBRT (23 Gy)
and RE to the right (111 Gy) and the left (172 Gy) lobe. The bar represents the
mean value between the right and left lobe, @(84) HCC, segmental
treatments, superselective
Figures 1 and 2 summarize the correlations between absorbed
doses and side effects to the liver and the lungs, highlighting
tolerated absorbed doses (green bars), limits for toxicity or rec-
ommendations (orange bars), and manifested toxicity (red bars).
Table 4 reports the fatal events documented in the literature due
to radiation liver toxicity (Table 4A) and radiation pneumonitis
(Table 4B).
Side effects to the liver
Some authors have distinguished between the classic radiation-
induced liver disease (RILD) associated to EBRT, and the occur-
rence of REILD (59), the two having different profiles. The man-
ifestation of RILD occurs typically 2–24 weeks after EBRT. It is
dominated by vascular injury to the central vein, which is the
most radiosensitive tissue in the hepatic microanatomy, char-
acterized by a wall thickening that leads to VOD. There is the
development of portal hypertension, ascites, and altered liver
function tests, in particular an increase of alkaline phosphatize
level, while liver enzymes and total bilirubin level may change
only slightly (85, 86). Instead, REILD manifests typically within
2 months after RE and can damage mainly the portal tracts. A suba-
cute and chronic portal triaditis could represent the effect of higher
absorbed doses in the portal triads. The common clinical effects
are ascites, jaundice, total bilirubin increase, increase in alka-
line phosphatase and GGT, and splenomegaly at various degrees,
which might suggest subclinical or low-grade portal hyperten-
sion (1, 12). The distinction between RILD (injury to the central
vein) and REILD (injury to the portal tracts) compares well with
the absorbed dose distribution at the microscopic level derived
by mathematical modeling of the microspheres within the ves-
sels (1, 60) (see section Activity Distribution at the Microscopic
Level).
www.frontiersin.org August 2014 | Volume 4 | Article 210 | 9
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cremonesi et al. Radioembolization: radiobiological and dosimetric perspective
FIGURE 2 | Lung absorbed doses (Gy) and tolerability. The graph shows
the lung absorbed doses (Gy) reported in the literature, with information
about the associated lung tolerability. The absorbed doses taken from the
literature are reported although these are derived without including the
attenuation correction. Absorbed dose values should be rescaled by an
average factor of 0.6 (12). Red bars represent radiation-induced pneumonitis
leading to death; orange bars represent the threshold for observed
radiation-induced pneumonitis or the limit recommended by the author; green
bars represent tolerated absorbed doses. The references are reported in
parenthesis after the name of the first author.
Liver toxicity is evaluated by assessment of enzymes and
metabolites, i.e., ALT, AST, alkaline phosphatize, albumin, biliru-
bin, INR, or clinical symptoms (clinically detectable ascites, bleed-
ing from esophageal varices, and encephalopathy). In patients with
HCC, it is difficult to assess whether liver toxicity is due to worsen-
ing of hepatic cirrhosis, to disease progression or to RE. Timing is
the argument generally adopted to consider a liver adverse event as
treatment related or not. Events within 3 or 6 months are usually
considered treatment related, depending on the authors. There is
a lack of consensus about the exact liver toxicity definition, which
encumbers data comparison. Mazzaferro et al. (75) introduced an
ad hoc definition of liver decompensation, with a wide acceptance
window (a cutoff of 6 months after treatment, including reversible
adverse events), while Garin et al. (14) choose a 3 months cutoff,
including only irreversible events and excluding cases attribut-
able to T progression or portal vein presence. This resulted, for
the same kind of HCC patients treated in the same way, in a liver
decompensation incidence of 36.5% for the first group, while 9.5%
for the second.
When reporting dose–effects to the liver, distinction needs to
be made between resin and glass spheres, as absorbed doses values
are not directly comparable (Table 2): for resin spheres, the mean
absorbed dose to the NL is generally reported, while for the glass
spheres the mean absorbed dose to the whole liver or treated lobe
is usually expressed. As can be seen from viewing Figures 1 and 2,
tolerance levels for glass spheres are higher in terms of grays.
Liver toxicity after resin spheres. Kennedy et al. (24) pre-
sented the results of 680 treatments on 515 patients. The median
prescribed activities were 2.0± 0.4 GBq (empirical method),
1.6± 0.5 GBq (BSA method), and 1.1± 0.6 GBq (actually deliv-
ered). REILD occurred in 28 treatments (4%) and lead to death.
Of these, in 21 of a single center, the activity to be adminis-
tered was decided by the empiric method, and 20 were a bilobar
approach. Unfortunately, the absorbed doses to NL are not avail-
able. According to the authors, REILD significantly correlated with
the administered activity, thus indirectly with the liver absorbed
dose. The high risk of death with method (i) lead to the rec-
ommendation to avoid the empirical method and whole liver
treatments (5).
Sangro et al. (59) observed an increased toxicity in patients
receiving an absorbed dose to NL of 37± 12 Gy versus 26± 12 Gy
(99mTc-MAA, partition model) (Figure 1). VOD was observed
only in patients who received chemotherapy. The incidence of
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Table 4 | (A) Fatal events due to liver failure; (B) Fatal events due to radiation pneumonitis.
Reference Type of
spheres
Method for activity
determination
No. of patients with
adverse events
leading to death
HCC or
metastases
Notes
(A)
Lau et al. (102) Resin Empirical 4% (3/71) HCC Liver failure but not RILD
Geschwind et al. (83) Glass 100 Gy to whole liver;
135–150 Gy to whole liver
1% (1/80) HCC 139 Gy to right lobe; 158 Gy left lobe
Goin et al. (81) Glass 50–150 Gy to the whole
liver or the lobe treated
5% (6/121) HCC In practice: 130 (34–268) Gy
Dancey et al. (82) Glass 100 Gy to whole liver 9% (2/22) HCC Absorbed doses of 90 and 107 Gy; whole
liver treatment (range given: 46–145 Gy)
Sangro et al. (101) Resin BSA; <60 Gy to NL 8% (2/24) HCC 53 Gy (2.43 GBq) and 46 Gy (2.04 GBq)
Kennedy et al. (24) Resin empirical 4.1% (28/515) HCC and
metastasis
In the same center using the Empirical
methodBSA 1.5% (7/515)
Strigari et al. (16) Resin BSA 11% (8/73) HCC (plus 15/73 pts with hepatic coma)
Bagni et al. (53) Resin BSA (1.6, 1.68, 1.3+1.3,
1.85+1.5, 1.85+1.5 GBq)
4% (5/135) Metastasis Mean absorbed dose to the liver: 35, 38 Gy
(single treatment); 37–68 Gy cumulative
Lam et al. (77) Resin BSA(1.5 GBq) 3% (1/31) Metastasis 21 Gy from EBRT and 71 Gy from RE
Glass 120 Gy to the treated liver
(7.3 GBq)
3% (1/31) HCC 23 Gy from EBRT and 172 Gy (left
lobe)+111 Gy (right lobe) from RE
(B)
Leung (89) Not
specified
Not specified 3/80 pts HCC LS within 13–46%, absorbed doses 10, 25,
and 25 Gy without attenuation correction,
corresponding to ∼6, 15, and 15 Gy with
attenuation correction
Dancey (82) Glass 100 Gy to the whole liver
(NL+T)
1/22 pts HCC LSF 39%; absorbed dose of 56 Gy without
attenuation correction, corresponding to
∼34 Gy with attenuation correction; previous
lung chronic disease and lung embolism
The absorbed doses values in the “Notes” column report the specific values given to patients who manifested a fatal event.
REILD was associated with young age (<55 years), diffuse disease,
bilobar treatment, previous chemotherapy and/or pre-existing
altered liver function, bilirubin level, and administered activity.
The results indicated as threshold for REILD the mean absorbed
dose of 40 Gy to NL.
The use of the LQM model as rationale of RE was proposed
by Cremonesi et al. (15), who applied the limit of 40 Gy to NL in
20 patients with liver metastasis treated with total liver approach.
The threshold value was extrapolated from the TD5,5 of EBRT, with
proper conversion to RE by the BED concept, using a limit of 35 Gy
(BED= 54 Gy, EQ2=TD5,5= 30 Gy) in a few patients, followed
by an absorbed dose escalation to 40 Gy (BED= 64 Gy). No toxi-
city was observed apart from transient elevation of liver enzymes.
The authors suggested the use of the LQM also as theoretical
basis to evaluate the risk/benefit balance of re-treatment or bilobar
approaches, which are empirically applied instead (72, 79, 80, 86).
Out for 135 patients, Bagni et al. (53) reported 5 cases (4%)
of liver failure that led to death 3–4 months after RE. The activ-
ity ranged from 1.3 to 1.85 GBq (BSA method). Simulation with
99mTc-MAA was not performed, but post-therapeutical 90Y-PET
images showed diffused radioactivity in the liver and reduced
tumor uptake. Voxel dosimetry was performed. Two patients
received a single treatment with mean absorbed doses to NL of
34.5 Gy (EQ2= 30 Gy, BED= 54 Gy) and 38.5 Gy (EQD2= 33 Gy,
BED= 61 Gy) assuming α/β= 2.5 Gy. The other three patients
underwent two treatments with cumulative mean absorbed doses
ranging from 37 to 68 Gy (EQD2: 31.8–76.5 Gy, BED: 57.3–
137.7 Gy). Details about the clinical status of the patients were not
reported, but the absorbed doses received also in the first treat-
ment adhere to the limits extrapolated from EBRT. These cases
with resin spheres showing – at least from imaging – nearly uni-
form irradiation of NL, are more closely reproducing the uniform
irradiation of EBRT.
Strigari et al. (16) applied to a nuclear medicine treatment
the radiobiological methods used in EBRT, pointing to the
methodology that should be used to describe the effects and to
plan any radiation treatment nowadays. The authors analyzed 73
HCC patients Voxel dosimetry was retrospectively assessed from
Bremsstrahlung images. They found that the mean absorbed dose
was a predictor for liver failure and a modified Lyman–Burman–
Kutcher model was applied to obtain a fitted NTCP curve with
toxicity >G1 as end-point. The parameters describing the NTCP
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were a TD50 of 52 Gy (95%CI, 44–61 Gy) and a slope of NTCP
versus dose of 0.28 Gy−1(95%CI, 0.18–0.60), assuming n= 1.
Di Dia et al. (51) applied the voxel dosimetry method to 99mTc-
MAA-SPECT images of 13 metastatic patients undergoing whole
RE with resin spheres, with a prescribed mean absorbed dose
of 40 Gy to NL (assuming an uniform distribution). No toxic-
ity was observed, as expected. In principle, higher activities could
have been administered according to the degree of non-uniformity
highlighted by the voxel dosimetry. Average doses, BED, EUBED,
and EUD, were calculated for several α and α/β values. EUD
was considered as possible new constraint, in place of the mean
absorbed dose. However, it was found that EUD is notably influ-
enced by the value of α. The authors conclude that the α parameter
needs to be identified for NL and the specific tumors in order to
apply radiobiological quantities for RE protocols.
Lau et al. integrated the clinical experience from literature in
a review to guide patient selection and activity planning for RE
with resin microspheres (42). In order to minimize fatal events,
the authors recommend 50 Gy as maximum limit in whole treat-
ments and 70 Gy to the NL lobe treated in lobar approach. Kao
et al. (22) did not find toxicity fulfilling these constraints.
Petitguillaume et al. (87) applied for the first time direct Per-
sonalized Monte Carlo Dosimetry (PMCD) to resin sphere treat-
ment. CT images created patient-specific voxel phantoms using the
OEDIPE software. 99mTc-MAA SPECT images of 10 patients were
combined to calculate absorbed dose at voxel level with MCNPX
Monte Carlo code. Activity prescription from PMCD and partition
model were compared, with or without including DVH criteria.
The use of PMCD resulted in higher administrable activity than
the partition model calculation. The allowed increase is on the
average of 27% if mean dose constraints are considered, and of
40% if DVH criteria are adopted.
Liver toxicity after glass spheres. Dancey et al. (82) treated 22
HCC patients (9 Okuda stage I, and 11 Okuda stage II) in a whole
liver approach. The median (range) absorbed dose to the whole
liver was 104 (46–145) Gy, and to the lungs was 13.0 (1.8–56.5) Gy
[with LF: 6.4 (1–39%)]. Two patients were treated a second time,
resulting in total liver doses of 100 and 209 Gy and lung doses of 43
and 36 Gy, respectively. Serious adverse events (severe, life threat-
ening, and death) occurred in 14 patients (63%), including three
deaths. The authors admit that the lack of detailed liver dosime-
try with distinction between T and NT parenchyma is a major
limitation of their study.
Sarfaraz et al. (54) first investigated the voxel activity distrib-
ution in one treated patient. The absorbed dose distribution was
retrospectively analyzed by 99mTc-MAA-SPECT images, with iso-
dose curves and DVHs derived forT and liver. The meanT and NL
doses were 163 and 58 Gy. No radiation hepatitis was reported for
this patient, in agreement with the reduced amount of liver irra-
diated with more than 110 Gy and with the use of glass spheres,
58 Gy is in fact much higher than the tolerance observed in resin
spheres and in EBRT.
Goin et al. (81) analyzed a group of 88 patients affected by
HCC. The results indicated that pre-treatment bilirubin and liver
absorbed dose were the most statistically significant factors asso-
ciated with an increased risk of liver toxicity. A limit of 150 Gy
for a single administration and of 268 Gy for a repeated RE were
considered as tolerated and reversible. The authors concluded that
no cases of serious RILD occurred, being the bilirubin increase,
and not the alkaline phosphatase, the mark accompanying ascites
in 33% of patients. However, they did not consider the definition
of REILD that possibly occurred.
Rhee et al. (72, 84) used CT angiography (CTA) in 14 patients
with unresectable HCC to super-selectively administer in liver
segments and to evaluate tumor absorbed doses. Activity was
planned in order to deliver 120 Gy to the target lobe. Estimated
absorbed doses to the lobe (before CTA) (100± 43 Gy, range:
35–169 Gy) were significantly lower than the actual absorbed
doses to the target segmental liver volume (after CTA) retro-
spectively calculated (348± 204 Gy, range: 105–857 Gy). Changes
in serum bilirubin level were statistically significant within nor-
mal levels and were not clinically relevant. Thirteen of 14
patients had no change in Child-Pugh class. This study sup-
ports that irradiation of a small organ fraction gives very limited
toxicity, enhancing that the well-known liver volume effect in
EBRT also applies in RE (see also section Comparing RE and
EBRT).
The relationship between cumulative lobar radiation dose and
liver toxicities in case of multiple RE procedures has been inves-
tigated by Young et al. (79). Forty-one patients affected by HCC
and classified according to the Okuda stage I (O-I, 20 patients)
and stage II [(O-II), 21 patients] disease were enrolled. The O-
I group received more treatments than the O-II group, and a
higher cumulative absorbed dose to the lobes, with average (range)
247 (88–482) Gy versus 198 (51–361) Gy. Toxicity was observed in
only 16% of patients. O-I patients received a greater cumulative
dose than O-II patients before liver function alteration: 390 versus
196 Gy, confirming different tolerance for different initial con-
ditions (section Comparing RE and EBRT). For O-I patients, a
higher cumulative absorbed dose was associated with occurrence
of one or more toxicities: 222 Gy (no toxicities) versus 390 Gy (≥1
toxicity), confirming that liver toxicities increase with increasing
cumulative radiation dose. It is worthy to note that the O-I group
manifesting greater tolerability received the cumulative therapy
in a higher number of treatments (2.65 versus 2.24 treatments in
average), possibly shifting the tolerance toward higher absorbed
dose values (see also section Comparing RE and EBRT).
Riaz et al. (80) further applied the segmental RE approach to 84
selected HCC patients. Activity was planned to deliver an absorbed
dose of 120 Gy to the lobe. The segment absorbed dose was esti-
mated with the hypothesis of uniform activity, but also with a
revised method based on the iodinated contrast medium distri-
bution (subjective assessed by the radiologist), in the attempt to
assess a T/NL ratio. The median dose to the segment was 521 Gy
(95%CI: 404–645 Gy) by the usual method, while it was 210 Gy
(95%CI: 107–270 Gy) with the revised method. The results high-
lighted that the T/NL uptake ratio has a great impact on evaluation,
remarking the importance of separate T and NL dosimetric eval-
uation. G3 and G4 toxicity rate was extremely low, confirming the
volume effect in RE (see also section Comparing RE and EBRT).
Chiesa et al. (13) retrospectively evaluated on 99mTc-MAA
SPECT images the T and NL absorbed doses of 52 HCC patients
lobarly injected according to the prescription of 120 Gy (75). Liver
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FIGURE 3 | Increase of risk of liver decompensation with mean
absorbed dose. Increase of the observed risk of liver decompensation
with whole parenchyma mean absorbed dose in intermediate/advanced
HCC patients with Basal Child-Pugh A5 treated with glass microspheres.
Reprinted with permission by Minerva Medica from Quarterly Journal of
Nuclear Medicine Molecular Imaging (13).
decompensation was defined according to Mazzaferro et al. (75).
Basal Child-Pugh strongly affected the toxicity incidence: 22%
for A5, 57% for A6, and 89% for B7 patients (univariate analy-
sis). In Child-Pugh A5 patients, absorbed dose averaged on NL
was 90 Gy (liver decompensation) versus 58 Gy (non-toxic treat-
ments). The experimental NTCP histogram as a function of NL
mean-absorbed dose is shown in Figure 3. A limit of about 70 Gy
for the mean absorbed dose to parenchyma can be assumed for
Child A5 patients treatment planning, corresponding to a 14% risk
of liver decompensation. This result is applicable only with glass
spheres decay interval of 3.75 days.
Side effects to the lungs
Significant shunting to the lungs is rather rare and avoidable by
appropriate patient exclusion criteria. It can lead to progressive
pulmonary insufficiency, with pulmonary fibrosis, and ultimately
radiation pneumonitis (88). Some authors report the acceptable
limit by means of LS percentage, others report the LS and absorbed
dose limits. Of relevance, the lung absorbed dose evaluations
that are reported in this paragraph and in Figure 2 are overes-
timated, because authors usually do not apply the attenuation
correction. The proper values – also for possible comparison with
EBRT – should be rescaled by an average factor of 0.6 (12). E.g.,
the limits of 30 and 50 Gy (40, 89) obtained with resin spheres
from non-attenuation corrected images, should be actually 18 and
30 Gy, much closer to the TD values from EBRT (TD5= 17.5 Gy;
TD50,5= 24.5 Gy) (70).
Resin spheres. Leung et al. (89) described 5/80 cases of radiation
pneumonitis, with 3 patients who died from respiratory failure.
The LS of these patients ranged from 13 to 46%, with associated
absorbed doses from 10 to 36 Gy. Recommendations of LS< 13%
(corresponding to 19 Gy for 3 GBq of microspheres injected) were
given, as 55% of the patients having this LS developed toxicity,
which was absent in patients with LS< 13%. Furthermore, 19 Gy
was indicated as the lower value to cause radiation pneumonitis.
From the same group, Ho et al. (40) suggested a LS of 20% and
an absorbed dose of 30 Gy as limits for risk of radiation pneu-
monitis in a single treatment, and a cumulative absorbed dose of
50 Gy not to be exceeded in repeated treatments.
In a recent paper regarding resin spheres, Lau et al. (42) recom-
mended that lung dose remains< 20 Gy, and never exceeds 25 Gy
(a more cautious approach than 30–50 Gy limits or LS< 15–30%).
Kao et al. (22) did not find any significant toxicity in 10 patients
receiving mean lung absorbed doses lower than 16 Gy.
Glass spheres. Dancey et al. (82) report the death of one patient
for radiation-induced pneumonitis (6 weeks after RE), with a LS of
39% and a lung absorbed dose of 56 Gy. In this single case of death
from radiation-induced pneumonitis, the patient had a chronic
lung disease, and a pulmonary embolism occurred 4 weeks before
RE. Instead two patients who received a dose to the lungs> 30 Gy
(36 and 43 Gy) did not develop any serious adverse pulmonary
events (86).
In the study by Salem et al. (88), 58 patients who underwent
RE received a lung absorbed dose> 30 Gy in single treatment
and 50 Gy cumulatively without developing radiation pneumo-
nia. Only 10/53 patients exhibited G1 lung toxicity. Absorbed
doses to the lungs higher than 100 Gy were tolerated without any
adverse effect. The authors conclude that the most applied lim-
its (30 Gy single, 50 Gy multiple), should be revised and that the
model – based on simulation by MAA, assuming uniform activ-
ity distribution in the lungs, with same limits for resin and glass
microspheres – might not be adequate.
Literature on EBRT has shown that the incidence of radiation
pneumonitis better correlates with the volume receiving a certain
absorbed dose (e.g., V20 or V30 as lung volume receiving at least
20 or 30 Gy) rather than the mean lung absorbed dose (90–92).
A better comparison with the EBRT models would require an
accurate evaluation of the activity biodistribution in the lung vas-
culature, incorporating the possible differences of resin and glass
microspheres. The microspheres distribution in the lungs is prob-
ably uneven, with a preferential distribution to the lung bases and
central parts, while a fraction is totally spared (7, 8). This may
happen because the distribution is affected by gravity and by the
blood flow (7). Moreover, the different number of particles could
lead to a greater micro-embolic effect with resin as compared with
glass microspheres also in the lungs (88, 89).
TUMOR RESPONSE
As point of attention in reviewing published data is that differ-
ent methods for tumor response evaluation have been considered,
based on CT (RECIST, dimensional criteria), EASL (density), or
PET parameters (e.g., SUV variation or total lesion glycolysis
(TLG), defined as product of the mean lesion SUV and the volume
of each lesion). The results available in the literature are sum-
marized in Figure 4, where distinction is made among absorbed
doses that are associated to response (green bars), thresholds for
response (orange bars) and T progression (red bars). Blue bars
specifically indicate PR (partial response) or SD (stable disease).
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FIGURE 4 |Tumor absorbed doses (Gy) and response. The graph shows
the T absorbed doses (Gy) reported in the literature, with information about
the associated response. Red bars represent progression, orange bars
represent the threshold for response, green bars observed response, and
blue bars specifically indicate PR (partial response) or SD (stable disease).
References are reported in parenthesis after the name of the first author.
mets, metastases; *response evaluation based on the variation of TLG in FDG
examinations; **non-responders based on the variation of TLG in FDG
examinations; §response evaluated based on the variation of SUV in FDG
examinations.
Resin spheres
Rhee et al. (84) evaluated the response of 42 patients who under-
went RE using glass and resin microspheres. In all cases, the
lobe but not the NL absorbed dose was evaluated. Using glass,
a higher median absorbed dose was delivered to each lobe (right
lobe 117 Gy, left lobe 108 Gy) than using resin (right 50.8 Gy, left
44.5 Gy). According to RECIST criteria, the 6-month disease con-
trol rate was similar with both microspheres (92% with glass and
94% with resin particles). This study gave the same clinical efficacy
from different median absorbed doses, as a consequence of differ-
ent number of microsphere per Gy and different non-uniformity
of dose deposition on microscopic scale, as a consequence of differ-
ent number of microsphere per Gy and different non-uniformity
of dose deposition on microscopic scale.
Ho et al. (40) estimated the correlation between tumor
absorbed doses and responses in a group of 71 patients affected
by HCC. Repeated (two to five) treatments were given to 15
patients. Tumor doses were estimated by the partition model. The
median absorbed dose at the first treatment was 225 Gy (range: 38–
748 Gy), while cumulatively was 302 Gy (range: 83–1580). 37% of
the patients showed a partial response at absorbed doses> 225 Gy,
in comparison with 10% at absorbed doses< 225 Gy. For survival,
with a cut-off value of 300 Gy, the median OS of 11 and 7 months
was observed in patients above and below the cutoff, respectively,
although the difference was not statistically significant.
Flamen et al. (35) made a retrospective dosimetry on 99mTc-
MAA–SPECT images of the PET response in 39 metastatic liver
lesions from colorectal cancer in a group of 8 patients treated
according to the BSA method (mean; range): 1.69 GBq; 1.33–
2.04 GBq. The paper reports the absorbed doses of the lesions
as a function of TLG variation (Figure 5), showing a clear trend,
and a correlation coefficient of R2= 0.26. This apparently low
value is similar to others found in nuclear medicine dosimetry
(93), and also in EBRT and might be attributed both to the mis-
location of points on the abscissa (dosimetric inaccuracy) and in
the ordinates (interpatient variability). Different response for the
same dose may also be deeply influenced by the lesion dimen-
sion. The median (95% CI) absorbed dose was 29 (1–98) Gy
and 66 (32–159) Gy in the poor (<50% TLG change) and the
good responders (TLG change> 50%), respectively. From MAA-
SPECT images using T/NL ratio of 1 as cut-off, a significant
metabolic response was predicted with a sensitivity of 89%, a
specificity of 65%, a positive predictive value of 71%, and a neg-
ative predictive value of 87%. Authors concluded that simulation
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FIGURE 5 |Tumor response related to variation of theTLG with
absorbed doses (Gy). T response by means of the TLG variation in
FDG-PET examinations versus T absorbed dose. Regression analysis
(R2 =0.26). Errata corrige of previously published data by Flamen et al. (35).
Data provided by the authors, personal communication.
with MAA can provide essential information for patients’ recruit-
ment to RE, allowing to predict the metabolic response. The
mean absorbed dose of the normal liver parenchyma was 39 Gy
(32–48 Gy), without toxicity.
Campbell et al. (39) retrospectively analyzed 14 patients
affected by metastases from colorectal cancer. The partition model
was applied with a T to NL ratio arbitrary of 3:1 and a patient-
specific ratio (99mTc-MAA SPECT images). The response rate was
evaluated comparing FDG-PET at baseline and 3 months after
RE. There was a statistically different absorbed dose between
the two methods. PET showed a mean decrease of 52% of total
SUV in tumors. There was a linear correlation between absorbed
dose and tumor response, but the tumor absorbed dose using
a patient-specific method was more predictive (R= 0.65). Two
good responses were observed at 255 and 317 Gy, for lesions of 5
and 13 g.
Strigari et al. (16) implemented a TCP model in RE analyzing
the outcome of 73 HCC patients. Response was defined accord-
ing to the RECIST and EASL criteria (94–96). The radiobiological
parameters used to compute BED for HCC were α/β= 10 and
T rep= 1.5 h. Experimental TCP was fitted with the hypothesis of
two different cellular radiosensitivity in T, obtaining two α-values
(0.001 and 0.05 Gy). Note that these values are definitively lower
than those obtained in EBRT (α= 0.01± 0.1/Gy) reported by Tai
et al. (97) after in vivo EBRT. TCP curve indicated that all tumors
with mean dose greater than 200 Gy showed a complete or par-
tial response. At lower doses, a higher response rate was found
using EASL rather than RECIST criteria, i.e., 90Y irradiation causes
changing in T structure rather than its shrinking. With an aver-
age dose of 110 Gy to the tumor, complete or partial response was
observed in 74 and 55% of patients according to the EASL and
RECIST criteria, respectively.
The paper by Lhommel et al. (17) describes the new method for
90Y-PET imaging using the low branch of e-/e+ pair production
in the 90Y decay (probability: 32× 10−6) and a TOF scanner. The
authors demonstrated that PET-based microsphere dosimetry is
feasible and quantitatively accurate, and they applied the method
in a patient treated with resin spheres. The absorbed dose distri-
bution well correlated with tumor control, with good response
in regions of high absorbed dose (average absorbed dose 104 Gy,
maximum 241 Gy), and tumor progression in regions only par-
tially targeted (average absorbed dose 29 Gy, maximum 70.6 Gy).
The advantage of this post-therapy technique is the possibility
to study the correlation based on the actual absorbed dose, i.e.,
bypassing the problem of correspondence between 99mTc-MAA
and microspheres, joined with the better PET spatial resolution
with respect to SPECT. It is not useful however, to provide a
treatment planning tool.
D’Arienzo et al. obtained high resolution post-RE 90Y images
by a non-TOF PET/CT scanner provided with bismuth germanate
(BGO) crystals (49, 50). The voxel dosimetry method was applied
for the analysis of a patient with liver metastases, administered
according to the BSA method (1.45 GBq) (50). The absorbed
dose distribution map and DVHs for both T and NL, showed
a wide heterogeneity. The mean absorbed dose to T was 139 Gy,
but two areas were distinguished: a hot margin receiving an aver-
age absorbed dose of 287 Gy (range: 100–700 Gy) and a cold area
with a necrotic core receiving an average absorbed dose of 70 Gy
with a large proportion of voxels receiving< 50 Gy. At the FDG-
PET control 6 months after RE, complete remission was observed
in highly irradiated T areas, while progression was observed in
the scarcely irradiated area, demonstrating correlation between
absorbed dose and T response, and the role of non-uniformity of
dose deposition. The authors conclude that an average radiation
dose> 100 Gy may sterilize liver metastases.
Kao et al. (22) highlighted the power of predictive dosime-
try in a study involving 10 patients with HCC and very different
baseline disease characteristics. The authors introduce the “plan-
ning target volume” concept, adapted from EBRT, and state that
“despite its popularity, the BSA method has a questionable radio-
biological basis and is scientifically inferior to MIRD methodol-
ogy.” The patients were therefore administered with resin micros-
phere using an artery-specific 99mTc-MAA-SPECT/CT partition
model. Median predicted absorbed doses were 106 Gy (95% CI,
105± 146 Gy) to T, 27 Gy (95% CI, 22± 33 Gy) to NL, and 2 Gy
(95% CI, 1.3± 7.3 Gy) to lungs. The results showed that a 100% T
response rate could be achieved with an absorbed dose of at least
91 Gy.
The same author (36) presented a study of 23 patients affected
by HCC and metastases treated with activities based on predic-
tive dosimetry as above. 90Y-PET images were acquired after RE
and absorbed dose distributions obtained by voxel dosimetry.
Dose–responses in tumor was analyzed considering the DVHs
(90Y-PET) or the mean absorbed doses (99mTc-MAA-SPECT) in
correlation with follow-up imaging or clinical findings (98, 99).
Interestingly, the concepts of D70 (the minimum absorbed dose
delivered to 70% of the T volume) and V100 (the percentage T
volume receiving≥ 100 Gy) were proposed for T reporting from
EBRT. D70= 100 Gy was derived as a threshold for complete ver-
sus incomplete responses. Comparing the mean absorbed doses
90Y-PET and 99mTc-MAA-SPECT imaging, a good correlation was
found in 7 lesions under near-ideal dosimetric conditions (i.e., case
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of technically success, T/NL ratio≥ 2, good activity coverage), with
a relative error ranging from−2 to 13%.
Glass spheres
In a study previously discussed for toxicity, Riaz et al. (80) planned
the activity in order to deliver 120 Gy to the lobe/segment, by the
mono-compartmental method. Retrospectively, for comparison
purposes, a method based on the iodinated contrast medium dis-
tribution was used to evaluate the absorbed dose to T and NL.
Tumor received 1214 (961–1546) Gy. The response rate evalu-
ated by WHO (dimension criteria) was 59% (after 7.2 months),
and that evaluated by EASL (density criteria) was 81% (after
1.2 months). The study confirms the correspondence of high effi-
cacy with high T absorbed doses. However, the difference of T
absorbed doses between responding (EASL 1279 [986–1626] Gy)
and non-responding (EASL (1118 [332–2139] Gy) lesions was
not statistically significant, possibly because of the questionable
method of assigning the T /NL uptake.
Sarfaraz et al. (100) used the standard method of 150 Gy to
the treated lobe to establish the administered activity. They ret-
rospectively analyzed 10 patients using the data from total body
images (99mTc-MAA scan) as input to the compartmental (parti-
tion) method. The activity distribution in the liver was found to
be highly non-uniform, with different T/NL uptakes. For a typical
patient, the absorbed doses to the T and NL were 402 and 118 Gy,
respectively. The NL median dose with non-compartmental and
compartmental model were statistically different (141± 12 Gy ver-
sus 117± 23 Gy). The authors pointed out the need to distinguish
T to NL absorbed dose in order to avoid high risk of over- or under-
dosage, and possibly to estimate the overall dose distribution.
In a subsequent paper (54), the same authors account the voxel
activity distribution in a patient from 99mTc-MAA SPECT images
retrospectively analyzed, with isodose curves and DVHs derived
for T and NL. The DVHs indicated that although the patient was
treated to the nominal whole liver dose of 110 Gy, only 16% of NL
and 83% of the T received a dose higher than 110 Gy. The mean T
absorbed dose was 163 Gy.
In a retrospective study, Garin et al. (14) analyzed 36 patients
with HCC. The activity was based on 99mTc-SPECT/CT images in
order to deliver an absorbed dose to the liver of 120± 20 Gy (with-
out exceeding 30 Gy to lungs). The absorbed dose to the T (DT)
and to NL were also determined. 69% of patients responded (EASL
criteria). A multivariate analysis identified DT as the only parame-
ter associated with response, with the value of 205 Gy as threshold
predictive of response, a sensitivity of 100%, and an accuracy of
91%. PFS and OS were 5.2 and 9 months whenDT < 205 Gy, whilst
with DT≥ 205 Gy they were, respectively, 14 and 18 months. This
study highlighted the utility of 99mTc-MAA SPECT/CT dosimetry,
in predicting both response and survival.
These preliminary results were confirmed in a larger cohort of
71 HCC patients (21), with the same threshold of DT= 205 Gy
for T response. The response rate was 79%, with a median DT
of 342 Gy and of 191 Gy for responding and non-responding T,
respectively, with a statistically significant difference. Based on
the predicted DT and DNL, 17 patients underwent a boosted RE
(increased injected activity with respect to 120 Gy prescription)
that provided a good response rate (77%) without increased
G3 liver toxicity. Median PFS and OS were only slightly differ-
ent from the previous study. In 33 PVT patients, the median
PFS and OS were 4.5 and 5 months when DT < 205 Gy, whilst
with DT≥ 205 Gy they were, respectively, 10 and 22 months.
The authors remark the predictivity of 99mTc-MAA SPECT/CT
dosimetry on response and OS, and point out the possibility to
adapt the treatment planning especially in patients with large T,
e.g., intensifying the treatment without increasing liver toxicity
(boosted RE concept).
In the retrospective dosimetry on 99mTc-MAA SPECT images
by Mazzaferro et al. (75), EASL lesion response (CR+PR) cor-
related with absorbed dose (Spearman’s r = 0.60; 95%CI, 0.41–
0.74; P < 0.001). Lesions lacking of objective response received
a median dose of 275 Gy, whereas responding tumors were
found to absorb 490 Gy (P < 0.0001). An efficacy threshold of
500 Gy significantly predicted the observed objective response
and limited to 20% the rate of non-responders (area under the
curve= 0.78).
TAKE HOME MESSAGES FROM DOSE–EFFECTS CORRELATIONS
For the first time in nuclear medicine therapy, a dose–effect rela-
tion was indicated (observed), even though data are sparse and
obtained with non-uniform methods. This is more evident for
lesions, while a liver toxicitydose relation is reported in fewer
papers. Several bias impede to find sharper dose thresholds: the
heterogeneity of the end points considered, different basal liver
conditions, the natural history of cirrhosis in HCC patients, the
previous chemotherapy cycles for metastatic cases. Dosimetric
methods are still not uniform but they are improving quickly. After
the application in peptide radionuclide therapy (10), the radiobi-
ological modeling (NTCP and TCP curves) inherited from EBRT
has been applied to RE to describe the observed clinical data (16)
and to plan treatments (13). The efforts made highlight several
interesting issues that fit dosimetric and radiobiological perspec-
tives. These are summarized for side effects andT responses in the
following.
Side effects
- Administered activity alone does not appear to be a valid pre-
dictor of treatment safety compared to accurate estimation of
absorbed dose (28 cases of death occurred although activities
were not particularly high) (24). The empirical method has
been excluded from recommendation. Despite its popularity,
the BSA method represents a non-dosimetric approach and is
radiobiologically questionable (22). The role of 99mTc-MAA
simulation is relevant, to avoid treatments with inappropriate
activity distribution (14, 53).
- For resin spheres, the dosimetry with 99mTc-MAA and the com-
partmental model was able to find out the indication for liver
toxicity beyond 40 Gy to the whole liver (35, 101) – which is
not far from EBRT limits (15). The BED50 of 93 Gy by Strigari
et al. (16) in HCC patients is not so far from the BED50 of 72 Gy
deduced from EBRT (70). In case of nearly uniform activity dis-
tribution, values for severe toxicity were comparable with those
from EBRT (53).
- For glass spheres, authors acknowledge that the lack of
distinction between T and NL is a major limitation (82, 100), as
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such distinction has a great impact on the evaluations derived
(e.g., median absorbed dose to the liver segment of 520 versus
210 Gy by the usual glass method versus the revised method)
(14, 21, 80). In any case, in glass spheres, increasing cumu-
lative absorbed doses were found to increment liver toxicities
(79). The NTCP reported in Figure 3 by Chiesa et al. is the
first indication of augmented risk with absorbed dose aver-
aged on the NL parenchyma for HCC patients. 70 Gy seems
a good value to keep the incidence of liver decompensation
below 20%.
- About lung tolerance, the present safety limits (dose< 30 Gy)
were obtained for resin spheres on planar images non-corrected
for attenuation. The correction leads this threshold close to
the known value from EBRT (17.5 Gy). For glass spheres, the
question is completely open.
- Dosimetry from post-RE images (Bremsstrahlung-SPECT but
above all 90Y-PET) could improve the dose–effect corre-
lations bypassing the problem of correspondence between
MAA and microspheres (16, 49, 50, 53). The voxel dosimetry
enriched the information about the degree of non-uniformity
(50, 51, 53).
- The LQM was proposed as rationale to guide therapy decisions
and absorbed dose-escalation studies involving re-treatment
and partial liver irradiations (volume effects). The radiobio-
logical methods used in EBRT to derive NTCP and TCP curves
have been applied to RE to predict toxicity and response (16).
- The radiobiological parameters can consistently influence the
radiobiological entities such as EUBED or EUD, and should be
determined specifically for the tissues under investigation, in NL
and different T. (51)
- The liver volume effect well known in EBRT has been confirmed
also in RE, where the irradiation of a small organ fraction gave
very limited toxicity (72, 80). A large irradiated volume with
high dose is a risk factor (21).
- As in EBRT, the basal liver status deriving from underly-
ing disease (cirrhosis) or concomitant or previous treatment
(chemotherapy, TACE) results in markedly different dose toler-
ance (13, 59, 79). A systematic absorbed dose-escalation study
would need the same conditions of the patients included (79).
Tumor response
- There is not a univocal evaluation criteria of T response (16, 35).
- In resin spheres, 99mTc-MAA has provided essential informa-
tion for patient recruitment to RE (35), preventing treatments
without proper activity distribution (53). Lesion dosimetry cor-
related with metabolic response (17, 35, 50) as well as with
radiologic response (14, 16, 39, 75).
- The voxel dosimetry approach is more and more applied, with
potential improvement of predictive power of dosimetry. DVHs
are derived, the degree of non-uniformity analyzed (17, 50,
51), and the EUBED, EUD, EQ2 parameters evaluated. Recently,
the “planning target volume” concept has been proposed with
D70 and V100 as parameters for response and toxicity as for
EBRT (22).
- There is clinical evidence of a same biological effect (toxicity and
efficacy) related to different median absorbed doses for glass and
resin microspheres (110–120 Gy versus 45–50 to the single lobe)
following the different number of spheres per GBq, i.e., per Gy
(2, 84).
- In glass spheres, the utility of 99mTc-MAA-SPECT/CT dosime-
try has been confirmed in predicting both response and survival,
and adapting the treatment planning especially in patients with
large T (14, 21). An absorbed dose of 205 Gy represents the
threshold for improved survival. Based on the dose distribution
analysis, some patients could benefit of a boosted RE without
increased G3 liver toxicity.
CONCLUSION
The proposed review offers a comprehensive summary of the
results and shows many successful steps reached when dosimetry
and radiobiological models have been used. Methods from EBRT
are ready to be inherited and/or adapted to RE applications. Some
dose–effects correlations are still weak or improvable, but others
have been robustly found, allowing to predict toxicity, response,
and survival. Individualized dosimetric treatment planning in
RE is feasible. This might definitely improve the management of
primary and metastatic liver cancer.
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